Delving into the real-world efficacy and safety of fecal microbiota or Rebyota outlined by Paul Feuerstadt, MD, paints a considerably reassuring picture of this therapeutic agent in dealing with recurrent C difficile. Rebyota has enjoyed FDA approval for over two years, and Dr. Feuerstadt, associate clinical professor of Medicine at Yale School of Medicine, who has remained actively involved with research and studies focused on this therapy, robustly advocates for the product’s inherent safety and effectiveness.
Dissecting an abstract from the Digestive Disease Week conference, he elucidates the deliberations held around five prospective trials, including two randomized control trials and several open label studies. This assessment incorporated an integrated safety analysis of 11,192 individuals who were administered at least one dose of Rebyota, and 676 who received a sole dose, in comparison with 83 who were given a placebo. The consistency of adverse events between placebo recipients and those treated with Rebyota is noteworthy.
This underlying similarity underscores that Rebyota does not increase the potential risk of adverse or serious adverse incidents, exemplified by the incidence of serious adverse events being 11.2% for a single Rebyota dose and 7.2% for a single placebo dose. A fraction of these trial participants were living with comorbidities, such as inflammatory bowel disease (IBD) and mild to moderate immunocompromised states. Dr. Feuerstadt highlights the findings of an open label study involving 71 IBD-affected participants, with the overall efficacy being 78.9% at the 8-week mark—80% in patients with Crohn’s disease, and 76.2% in those with ulcerative colitis.
Overall, the treatment response was very congruent with phase 3 data and the broader open label group. For immunocompromised individuals, Rebyota demonstrated a strong efficacy. Safety remains quintessential and the safety profiles were consistent, regardless of immunocompromised state or IBD.
As per the American Gastroenterological Association’s guidelines of February 2024, while microbiota restoration might be considered using FDA approved products in immune-competent individuals, data was considered lacking for the immune-compromised. New evidence from a phase 3 open-label study with 140 mildly to moderately immune-compromised participants, vindicates Dr. Feurestadt’s conviction about Rebyota’s safety in this population.